articleFrontiers in OncologyApr 22, 2014GOLD OA

Targeting PI3K/mTOR Signaling in Cancer

AAAlexandre Arcaro

University of Bern · Bern University of Applied Sciences · +2 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.

Citation impact

1,030
total citations
FWCI
32.30
Percentile
100%
References
83
Citations per year

Authors

1
  • AA
    Alexandre ArcaroCorresponding

    University of Bern, Bern University of Applied Sciences, University Hospital Foundation, Policlinico San Matteo Fondazione

Topics & keywords

Keywords
  • PI3K/AKT/mTOR pathway
  • Protein kinase B
  • mTORC2
  • Signal transduction
  • RPTOR
  • Phosphatidylinositol
  • Cancer research
  • Biology
No related works found for this paper.

Funding